New Data From Study Reinforces Safety Profile of Genentech's Hemlibra® in People with Hemophilia A
The following is a press release from Genentech. Genentech, a member of the Roche Group announced results from the second interim analysis of the Phase IIIb STASEY study, which reinforce the safety profile of Hemlibra® (emicizumab-kxwh) characterized in the Phase III HAVEN clinical program. In the STASEY study, Hemlibra was effective with no new safety […]
Spark Therapeutics Announces Updated Data on Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
The following is an excerpt from a press release from Spark Therapeutics. Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced updated data from three dose cohorts of the ongoing Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia […]